Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma

National Taiwan University Hospital100 enrolled

Overview

The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients.

This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Hepatocellular Carcinoma

Interventions

The imaging biomarkers determined by MR-PETDEVICE

The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).

Eligibility

Sex: ALLMin age: 20 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Prior Informed Consent Form 2. At least one measurable tumor, according to RECIST version 1.1. 3. Age \> 20 years. 4. ECOG performance status 0 or 1. 5. Life expectancy \> 3 months. 6. Confirmed Diagnosis of HCC 7. Adequate renal function (Serum creatinine ≦ 1.5 x upper limit of normal). Exclusion Criteria: 1. Age \<20 years old 2. Pregnancy 3. Contraindication for MRI: claustrophobia or MR non-compatible devices 4. Contraindication for MR contrast medium: severe adverse reaction or impaired renal function (Cre \> 2.0) 5. History of other malignancy

Locations (1)

National Taiwan University Hospital

Taipei, Taiwan

RECRUITING

Outcomes

Primary Outcomes

The recurrence rate at 3 months after treatment

Time frame: 3 months

Secondary Outcomes

The overall survival after treatment

Time frame: 1 year

Central Contacts

Ting-Fang Shih, MD

CONTACT

+886-2-23123456 ttfshih@ntu.edu.tw

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.